The Gut–Kidney Dialogue: Unraveling the Microbial Symphony in Renal Fibrosis

Renal fibrosis is a maladaptive pathological endpoint common to the diverse etiologies of chronic kidney disease (CKD), resulting in irreversible nephron loss and functional decline. Emerging evidence has highlighted the potential role of the gut microbiota in renal fibrosis through bidirectional interactions between the gut and kidney. In animal models, broad-spectrum antibiotic regimens have been confirmed to attenuate renal fibrosis, whereas fecal microbiota transplantation from fibrotic donors transmits renal disease in recipient germ-free mice, providing rudimentary evidence of microbial causality. Human-based studies have demonstrated that, in patients with CKD exhibiting progressive fibrosis, there are modifications in the composition of the gut microbiota, including decreased microbial variety and shifts in the distribution of specific bacterial groups. Furthermore, metabolomic profiling revealed that the severity of fibrosis was independently predicted by increased levels of circulating trimethylamine N-oxide and indoxyl sulfate. Preliminary clinical studies exploring the therapeutic potential of regulating the gut microbiota have demonstrated promising results. Interventions, such as high-purity probiotic formulations, result in improved renal function and decreased levels of fibrotic markers. These findings suggest a potential correlation between gut microbiota dysbiosis and renal fibrosis. However, further research is necessary to determine the causal correlations, elucidate the underlying mechanisms, and identify specific microbial species and metabolites related to the regulation of renal fibrosis. This review provides a systematic summary of the current understanding of the important connection between gut microbiota dysbiosis and renal fibrosis. Understanding the influence of gut microbiota on renal fibrosis may open new avenues for the development of innovative therapeutic strategies to prevent or manage renal fibrosis and its associated complications.

Authors

Institutions

Publication Details

Journal
The FASEB Journal
Published
2025-10-23
DOI
https://doi.org/10.1096/fj.202502675r
Citations
3
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
4.29

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Gut–Kidney Dialogue: Unraveling the Microbial Symphony in Renal Fibrosis

Shaokang Pan, Zi‐Hui Mao, Qing Zhang, Zhangsuo Liu et al.
3 citations
The FASEB Journal
Dialysis and Renal Disease Management
4.29
article

The Gut–Kidney Dialogue: Unraveling the Microbial Symphony in Renal Fibrosis

Shaokang Pan, Zi‐Hui Mao, Qing Zhang, Zhangsuo Liu, Duopin Li, Dongwei Liu, Xiaoya Zhang, Yingjin Qiao, Qi Feng, Y. Liu, Jingfang Chen
article en
3 citations

Abstract

Renal fibrosis is a maladaptive pathological endpoint common to the diverse etiologies of chronic kidney disease (CKD), resulting in irreversible nephron loss and functional decline. Emerging evidence has highlighted the potential role of the gut microbiota in renal fibrosis through bidirectional interactions between the gut and kidney. In animal models, broad-spectrum antibiotic regimens have been confirmed to attenuate renal fibrosis, whereas fecal microbiota transplantation from fibrotic donors transmits renal disease in recipient germ-free mice, providing rudimentary evidence of microbial causality. Human-based studies have demonstrated that, in patients with CKD exhibiting progressive fibrosis, there are modifications in the composition of the gut microbiota, including decreased microbial variety and shifts in the distribution of specific bacterial groups. Furthermore, metabolomic profiling revealed that the severity of fibrosis was independently predicted by increased levels of circulating trimethylamine N-oxide and indoxyl sulfate. Preliminary clinical studies exploring the therapeutic potential of regulating the gut microbiota have demonstrated promising results. Interventions, such as high-purity probiotic formulations, result in improved renal function and decreased levels of fibrotic markers. These findings suggest a potential correlation between gut microbiota dysbiosis and renal fibrosis. However, further research is necessary to determine the causal correlations, elucidate the underlying mechanisms, and identify specific microbial species and metabolites related to the regulation of renal fibrosis. This review provides a systematic summary of the current understanding of the important connection between gut microbiota dysbiosis and renal fibrosis. Understanding the influence of gut microbiota on renal fibrosis may open new avenues for the development of innovative therapeutic strategies to prevent or manage renal fibrosis and its associated complications.

The FASEB JournalVol. 39(20)
Zhengzhou University (CN), Ministry of Education (IR), First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN), First Affiliated Hospital of Zhengzhou University (CN)
National Natural Science Foundation of China, Zhengzhou University, Natural Science Foundation of Henan Province, Young Scientists Fund
Openalex Percentile: Top 5%
Dialysis and Renal Disease Management
4.29
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.